All News
Why should rheumatologists discuss exercise in PMR?
My colleague says, “I simply refer to physiotherapy. I don’t have time to discuss exercises, we need that time to discuss medications, side-effects, etc.” I sympathise. How do we promote activity and muscle strength among our patients?
Read Article
FDA Approves Infliximab Biosimilar for Subcutaneous Use
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
Read Article
Subcutaneous Biosimilars? (10.27.2023)
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
Read Article
Anti-Phospholipid Antibodies - Infrequent in Certain Groups
d
MedPage Today
Among patients with systemic lupus erythematosus (SLE), high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black and Asian individuals, researchers found.
Read Article
TNR - Controversies in PMR
A TNR Panel discussion on controversies in PMR: diagnosis, imaging, PCP roles, Lumping vs. Splitting.
Featuring Drs. Sarah Mackie, Wolfgang Schmidt, and Len Calabrese.
Moderated by Dr. David Liew.
Recorded on 10/24/2023
Read Article
Universal Imaging for GCA in #PMR? Not So Fast
https://t.co/p581kXSzAb https://t.co/UIQjCxAzym
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Remsima, an infliximab biosimilar, has been FDA. Celltrion has rebranded this as Zymfentra, for maintenance therapy in adults with moderately to severely active Ulcerative colitis and Crohn's disease following (after giving IV infliximab) https://t.co/3hb5Z7L9uw https://t.co/4gvSurl1nM
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Lupus Management Recommendations
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
https://t.co/9PKvsEUTM3 https://t.co/gElp6tyEQZ
Dr. John Cush RheumNow ( View Tweet)
JAKne? Systematic review &meta-analysis (25 studies, 10 839 pts), JAK inhibitor use was associated with an elevated odds of acne (OR 3-5 for UPA, TOFA, BARI, Deucra; but higher for abrocitinib (OR 13.5). Seen in Derm pts but hardly at all in Rheum pts https://t.co/0XYeLLPDlK https://t.co/xN0PR1gj08
Dr. John Cush RheumNow ( View Tweet)
Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure
Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/KtdQgTvw4o https://t.co/R70sj3oYPH
Dr. John Cush RheumNow ( View Tweet)
Genetic links for Raynauds Phen (RP): Large GWAS study of 5147 RP cases in the UK Biobank cohort shows 2 robust and strong (p < 4.8 × 10−13) novel loci A) ADRA2A (rs7090046, OR per allele: 1.26) & B) IRX1 (rs12653958, OR: 1.17) as candidate causal genes https://t.co/Jho4CKmITU https://t.co/Gstxdejpc0
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/7OsdPYWukv https://t.co/QoCxR04bJD
Links:
Dr. John Cush RheumNow ( View Tweet)
When #PMR Strikes Young, It Hits Hard
In this blogpost I want to talk about “young PMR”: when people develop PMR in what should be the prime of their lives. By this I mean people under 65, and even people under 50.
https://t.co/jHlppnddFf https://t.co/aB81hrYyHX
Dr. John Cush RheumNow ( View Tweet)
Controversies in #PMR
A TNR Panel discussion on controversies in PMR: diagnosis, imaging, PCP roles, Lumping vs. Splitting.
Featuring Drs. Sarah Mackie, Wolfgang Schmidt, and Len Calabrese.
Moderated by Dr. David Liew.
https://t.co/QLkypnPA2G https://t.co/y5EiLkB2yq
Dr. John Cush RheumNow ( View Tweet)
#PMR Mythbusters: PMR is Only Proximal
https://t.co/tRed7Zsaxi https://t.co/PWP5boH6NA
Dr. John Cush RheumNow ( View Tweet)
ACR 2022 Guideline on Glucocorticoid-Induced Osteoporosis
The ACR has published its updated recommendations for prevention and treatment of GIOP for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.
https://t.co/oKVovOafl7 https://t.co/irxsAxMwKA
Dr. John Cush RheumNow ( View Tweet)
#PMR and Telemedicine: do we really need an office visit?
Can we use a synchronous audiovisual visit or a rheumatology eConsult to evaluate the patient's symptoms quickly? Does it allow us to make an accurate diagnosis?
https://t.co/JTAYstzDk8 https://t.co/NNvYfdkm2K
Dr. John Cush RheumNow ( View Tweet)
CMAJ analysis of 28 studies & 24 million pts Rx opioids suggest a higher risk of opioid overdose w/: high-dose opioids, fentanyl, multiple opioid Rxs, overdose Hx, Dx of substance use, depression, bipolar, mental illness, pancreatitis https://t.co/FprgoaTvXR https://t.co/G0QjNJTezu
Dr. John Cush RheumNow ( View Tweet)
#PMR Polymyalgia rheumatica is very common, yet there is little research on the Dx & Management of PMR by #PCPs! Mayo study prevalence 701 per 100,000 (women=870 and men =508 per 100,000 population). https://t.co/7JZFeRPRnn https://t.co/0JoaXL4qv0
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023.
https://t.co/Wdk4tvnlRz https://t.co/YFdvfbyrpJ
Links:
Dr. John Cush RheumNow ( View Tweet)